Atlas Trials

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Clinical trial NCT04706598 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04706598
Sponsor
Fudan University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Urinary Bladder NeoplasmsImmunotherapy
Start date
2021-06-09
Primary completion
2024-07-11
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.